| Date | Title | Description |
| 14.01.2026 | AirNexis Therapeutics Secures $200M for Groundbreaking COPD Treatment AN01 | AirNexis Therapeutics emerged, securing $200 million in Series A funding. This substantial capital infusion targets chronic obstructive pulmonary disease (COPD). The company focuses on developing AN01, a novel dual PDE3/4 inhibitor. AN01 is... |
| 12.01.2026 | AirNexis Therapeutics Raises $200M in Series A Funding | AirNexis Therapeutics, a Palo Alto, CA-based clinical stage biotech company developing therapeutics for pulmonary diseases, raised $200M in Series A funding.
The round was led by Frazier Life Sciences, with participation from OrbiMed, SR On... |
| 11.01.2026 | AirNexis Therapeutics Launches With $200 Million Series A To Advance Phase 2 Dual PDE3/4 Inhibitor AN01 For COPD | AirNexis Therapeutics has launched as a clinical-stage biotechnology company focused on pulmonary diseases, closing a $200 million Series A financing and securing an in-license to a Phase 2 dual PDE3/4 inhibitor for chronic obstructive pulm... |
| 06.11.2025 | Braveheart Bio Launches With $185 Million Series A To Advance Treatment For Hypertrophic Cardiomyopathy | Braveheart Bio, a biotechnology company focused on developing therapies for hypertrophic cardiomyopathy (HCM) and related cardiovascular conditions, has launched with $185 million in Series A financing. The investment was led by Andreessen ... |
| 05.11.2025 | Braveheart Bio Raises $185M in Series A Funding | Braveheart Bio, a San Francisco, CA-based clinical-stage biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy (HCM) and related conditions, raised $185M in Series A financing.
Backers included Andreessen Horow... |
| 07.01.2025 | Jeito Capital's Bold Moves in Biopharma: A Strategic Investment Landscape | In the world of biopharma, where innovation is the lifeblood, Jeito Capital is making waves. This Paris-based private equity fund is not just dipping its toes; it’s diving deep into the ocean of clinical-stage biotech. With a recent investm... |
| 07.01.2025 | French PE fund Jeito Capital invests in global biopharma growth with Aviceda and XyloCor Therapeutics | Paris-based Jeito Capital, a PE fund focused on biopharma innovation, has furthered its position as a player in global healthcare investment with two major contributions to clinical-stage biotech companies Aviceda Therapeutics and XyloCor T... |
| 07.01.2025 | Aviceda raises $207M series C to take geographic atrophy drug through phase 3 | Aviceda Therapeutics has secured $207.5 million in series C funds as the immunomodulator-focused biotech awaits a phase 3 readout this year for its lead eye disease drug.
The round was co-led by the healthcare funds Omega Funds and TCGX, wi... |
| 03.07.2023 | Startup led by former Seagen CEO Clay Siegall merges with public company in $125M deal | Clay Siegall. (Seagen Photo)
Morphimmune, a biotech company led by former Seagen CEO Clay Siegall, is merging with a public biotech company, Immunome, in a deal boosted with $125 million from private investors.
Siegall will serve as CEO, pr... |
